研究显示，停药1 年内，心血管死亡/心衰住院风险显著增加，停用RAS抑制剂/ARNI可导致心血管死亡/心衰住院风险增加38%，停用MRA可导致风险增加36%，但停用β受体阻滞剂 影响不大。 与LVEF 改善至≥50%的患者相比，LVEF改善至40%~49%的患者如停用β受体阻滞剂，心血管死亡/心衰住院风险更高。这表明，在LVEF改善至50%之前持续使用β受体阻滞剂，预后可能会更好。

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

The researchers found that the withdrawal rates at the time of the improved EF registration were 4.4% for RASi/ARNi, 3.3% for BBL, and 17.2% for MRA. Lower use of other heart failure medications ...

The following is a summary of "Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death ...

“Our results show that heart failure medications continue to provide ... the current recommendation to continue with RASi/ARNi and MRA treatment, but also opens up the possibility of ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure in the EU, fulfilling a key 2025 pipeline objective. The pharma group ...

Heart failure is a serious, chronic condition. While medication can help the heart recover and improve its function, this study suggests that the medications themselves may continue to protect the ...